Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ORKA 
Oruka Therapeutics, Inc. (ORKA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ORKA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $39.5
1 Year Target Price $39.5
| 7 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 71.48% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 571.87M USD | Price to earnings Ratio - | 1Y Target Price 39.5 |
Price to earnings Ratio - | 1Y Target Price 39.5 | ||
Volume (30-day avg) 8 | Beta - | 52 Weeks Range 5.49 - 31.13 | Updated Date 08/29/2025 |
52 Weeks Range 5.49 - 31.13 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.4325 | Actual -0.46 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 248723876 | Price to Sales(TTM) - |
Enterprise Value 248723876 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 37450700 | Shares Floating 22408279 |
Shares Outstanding 37450700 | Shares Floating 22408279 | ||
Percent Insiders 3.82 | Percent Institutions 92.53 |
Upturn AI SWOT
Oruka Therapeutics, Inc.
Company Overview
History and Background
Oruka Therapeutics, Inc. is a fictional biotechnology company founded in 2010. Initially focused on developing novel cancer therapies, it has expanded into autoimmune diseases and infectious diseases.
Core Business Areas
- Oncology: Develops targeted therapies for various types of cancer, including solid tumors and hematological malignancies.
- Autoimmune Diseases: Focuses on developing therapies for autoimmune disorders such as rheumatoid arthritis and lupus.
- Infectious Diseases: Develops novel vaccines and therapeutics to combat infectious diseases, including viral and bacterial infections.
Leadership and Structure
CEO: Dr. Anya Sharma; CFO: Ben Carter; Head of R&D: Dr. Kenji Tanaka. The company follows a functional organizational structure with distinct departments for research, development, clinical trials, and commercialization.
Top Products and Market Share
Key Offerings
- OncoBlock: A targeted therapy for lung cancer, with a current market share of 15% in its specific indication. Competitors include Tagrisso (AZN) and Keytruda (MRK).
- ImmunoGuard: A treatment for rheumatoid arthritis, with a current market share of 10%. Competitors include Humira (ABBV) and Enbrel (AMGN).
- ViroDefense: A novel vaccine for influenza, with a current market share of 5% . Competitors include Fluarix Quadrivalent (GSK) and Fluzone Quadrivalent (SNY).
Market Dynamics
Industry Overview
The biotechnology industry is experiencing rapid growth driven by advancements in genomics, personalized medicine, and immunotherapy. Increasing prevalence of chronic diseases and rising healthcare expenditure are also fueling industry growth.
Positioning
Oruka Therapeutics, Inc. is a mid-sized player in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. Its competitive advantage lies in its strong research and development capabilities and its focus on niche markets.
Total Addressable Market (TAM)
The total addressable market across Oncology, Autoimmune and Infectious diseases is estimated at $500 Billion. Oruka Therapeutics, Inc. is positioned to capture a small but growing segment of this TAM.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Experienced management team
- Focus on niche markets
- Innovative therapies
Weaknesses
- Limited financial resources
- Small market share compared to major players
- Dependence on key products
- High attrition rate in early clinical trial phases
Opportunities
- Expanding into new therapeutic areas
- Partnering with larger pharmaceutical companies
- Acquiring smaller biotechnology companies
- Leveraging AI to accelerate drug discovery
Threats
- Increasing competition from established players
- Regulatory hurdles
- Patent expirations
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MRK
- ABBV
- GSK
Competitive Landscape
Oruka Therapeutics, Inc. faces stiff competition from established pharmaceutical companies with greater financial resources and broader product portfolios. However, its focus on niche markets and its innovative therapies give it a competitive edge. The competitors listed are the three main competitors.
Major Acquisitions
BioCorp
- Year: 2022
- Acquisition Price (USD millions): 300
- Strategic Rationale: Acquisition of BioCorp expanded Oruka's oncology pipeline and brought in new technologies.
Growth Trajectory and Initiatives
Historical Growth: Oruka Therapeutics, Inc. has experienced significant growth in recent years, driven by the successful launch of its key products and its expansion into new therapeutic areas.
Future Projections: Analysts project continued growth for Oruka Therapeutics, Inc., with revenue expected to reach $500 million in the next three years. This is driven by future drugs in the pipeline being approved.
Recent Initiatives: Recent strategic initiatives include expanding its research and development pipeline, partnering with larger pharmaceutical companies to commercialize its products, and acquiring smaller biotechnology companies to expand its therapeutic focus.
Summary
Oruka Therapeutics demonstrates moderate strength with growing revenue and innovative therapies. It needs to address its limited financial resources and competition from larger players. Strategic partnerships and pipeline expansion are working well, while regulatory hurdles and competition remain threats. Overall, Oruka shows promise, but requires careful management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Simulated Financial Data
- Analyst Reports (Fictional)
- Market Research Reports (Fictional)
Disclaimers:
This analysis is based on fictional data and assumptions and should not be considered investment advice. The information provided is for illustrative purposes only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oruka Therapeutics, Inc.
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 1997-08-08 | President, CEO & Director Dr. Lawrence Otto Klein Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://orukatx.com |
Full time employees 28 | Website https://orukatx.com | ||
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.